ABSTRACT
The role of allogeneic stem cell transplant in advanced acute promyelocytic leukemia patients who received standard first- and second-line therapy is still unknown. We report the outcome of 31 acute promyelocytic leukemia patients (median age 39 years) who underwent allogeneic transplant in second remission (n=15) or beyond (n=16). Sixteen patients were real-time polymerase chain reaction positive and 15 negative for PML/RARA pre-transplant. The 4-year overall survival was 62% and 31% for patients transplanted in second remission and beyond, respectively (P=0.05), and 64% and 27% for patients with pre-transplant negative and positive real-time polymerase chain reaction, respectively (P=0.03). The 4-year cumulative incidence of relapse was 32% and 44% for patients transplanted in second remission and beyond, respectively (P=0.37), and 30% and 47% for patients transplanted with negative and positive real-time polymerase chain reaction, respectively (P=0.30). Transplant-related mortality was 19.6%. In conclusion, allogeneic transplant is effective in advanced acute promyelocytic leukemia in the all-trans-retinoic acid and arsenic trioxide era, and should be considered once relapse is diagnosed.
Free PMC Article
Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era
Riferimento:
Haematologica. 2012 Nov;97(11):1731-5.
Autori:
Ramadan SM, Di Veroli A, Camboni A, Breccia M, Iori AP, Aversa F, Cupelli L, Papayannidis C, Bacigalupo A, Arcese W, Lo-Coco F. safaanci@yahoo.com
Fonte:
Haematologica. 2012 Nov;97(11):1731-5.
Anno:
2012
Azione:
Il trapianto allogenico di cellule staminali è efficace in particolare nella leucemia promielocitica acuta nell'era dell'acido all-trans-retinoico ed del triossido di arsenico.
Target:
Acido all-trans-retinoico ed del triossido di arsenico/leucemia promielocitica acuta
Sostanze: